Hospira, Inc. (Hospira), a US based medical devices company, has elected Heino von Prondzynski to its board of directors. Von Prondzynski brings strong executive management and diverse global experience from leadership positions held at multinational healthcare companies. Von Prondzynski was previously chief executive officer of Roche Diagnostics and a member of the executive committee of F. Hoffman-La Roche Ltd. from early 2000 to 2005.
“Heino has an impressive track record of achievement in the healthcare industry and significant experience in delivering global growth and expansion,” said Christopher B. Begley, chairman and chief executive officer. “His interest in talent development and passion for driving product innovation also make him an excellent and complementary addition to the Hospira board.”
While at Roche Ltd, he brought Roche Diagnostics, which included diabetes, near-patient testing, centralized diagnostics and applied science to global market leadership and record industry-standard profitability ratios. He also drove significant growth through an expansion of the molecular diagnostics portfolio and entrance into the blood-screening market. From 1996 to 2000, von Prondzynski held several executive positions, including president of its vaccine business, at Chiron Corporation, a multinational firm that develops biopharmaceuticals, vaccines and blood-testing products. Earlier in his career, von Prondzynski held sales and marketing and general management positions at Bayer A.G.
Von Prondzynski is on the boards of Koninklijke Philips Electronics N.V. (Royal Philips Electronics Inc.), Qiagen N.V., BB Medtech A.G. and Epigenomics A.G.
Born in Germany, now living in Switzerland, von Prondzynski studied mathematics, geography and history at Westfälische Wilhelms University of Münster in Germany.